Wisconsin companies that won federal research and development grants totaling $33.7 million will be honored during the annual Small Business Innovation Research awards ceremony during the Wisconsin Early Stage Symposium. ...
With more than $900 million in total investment across all academic fields, the University of Wisconsin-Madison has claimed the number two spot in university research, according to the National Science Foundation. UW-Madison also outpaced the likes of Harvard, Purdue, and the University of Texas to...
With regard to the recently enacted state budget, columnist Tom Still asks the $57 billion question: what does this tax-and-spend plan actually accomplish over the next two years? In this edition of Inside Wisconsin, he supplies a few answers, including renewal and expansion of the...
Two consumer advocacy groups that support rejection of stem cell patents held by the Wisconsin Alumni Research Foundation have filed formal comments saying that attempts to amend the patents should not save them from being overturned. In comments submitted last week, the Foundation for Taxpayer...
This year's global pharma company ranking had a few surprises, especially the news that Pfizer is no longer the leader of the sales pack, according to columnist Michael Rosen. In this edition of Yer Biotech Blues, Rosen notes that Pfizer has been surpassed by Johnson...
Citing his expertise in chemistry, the Germantown-based Cambridge Major Laboratories has added University of Illinois professor John Hartwig as scientific advisor. Cambridge Major produces pharmaceutical intermediates and other organic chemicals for pharmaceutical and biotechnology companies....
The signs of a slowdown are evident in the housing credit crunch, slower retail sales, and record oil prices, but investment opportunity remains, according to Inside Wisconsin columnist Tom Still. While parts of the economy are unsettled, he reminds us that new ideas and companies...
OpGen and In-Q-Tel, a firm that identifies technology solutions for the U.S. intelligence community, have partnered in what the companies are calling a strategic investment and development agreement. Colin Dykes, OpGen's chief scientific officer, says the agreement is aligned with OpGen's move to deliver stand-alone...
Quintessence Biosciences, a Madison biopharmaceutical company focused on development of cancer therapies, said its lead cancer drug candidate remains on track to enter Phase I clinical trials in early 2008. The company is trying to develop a pipeline of cancer-fighting drugs based on its EVade...
The annual Elevator Pitch Olympics are back, as are the entrepreneurs and investors who will engage in them next month at the annual Wisconsin Early-Stage Symposium. Thus far, 50 companies have applied for a chance to pitch to investors, and about 30 eventually will be...